Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
LXEO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $6.63M fell 60.1% year over year, behind the -13.0% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.0% from the prior quarter. Over 3 fiscal years it compounded at +55.9% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +43.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.63M-4.0% QoQ
- Last fiscal yearDec 2025
- $45.46M+43.5% YoY
- LTMMar 2026
- $35.46M-13.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 45.46M USD
- Year-over-year change
- +43.5%
- 4-year CAGR
- +58.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.46M | +43.5% |
| FY2024 | 2024-12-31 | 31.68M | +105.9% |
| FY2023 | 2023-12-31 | 15.38M | +28.2% |
| FY2022 | 2022-12-31 | 12M | +67.3% |
| FY2021 | 2021-12-31 | 7.17M | — |
Selling, General & Admin vs competitors
How LXEO compares with its peers on the latest reported figures
- LXEO's LTM Mar 2026 selling, general & admin of $35.46M is the 6th highest of the 11 companies compared; the peer median is $31.46M.
- Its year-over-year change of -13.0% is the 8th highest of 10, against a peer median of +18.2%.
- Over three fiscal years its annual growth of +55.9% compares with a peer median of +15.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $256.23M | +54.0% | +20.4% | 117.7% | |
| LTM Mar 2026 | $99.54M | -33.2% | -27.7% | 46.3% | |
| LTM Mar 2026 | $38.19M | +65.9% | +17.2% | — | |
| LTM Mar 2026 | $37.43M | +18.7% | +65.2% | — | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M | -13.0% | +55.9% | — |
| LTM Mar 2026 | $26.76M | +58.7% | +29.7% | — | |
| LTM Mar 2026 | $23.59M | — | +2.2% | 2560.2% | |
| LTM Mar 2026 | $19.82M | +7.4% | +14.2% | — | |
| LTM Mar 2026 | $19.76M | -28.1% | -0.2% | 3951.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $17.4M | +18.2% | +41.6% | — |
| Peer median (excluding LXEO) | $31.46M | +18.2% | +15.7% | 117.7% | |
Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.66M | 654K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.66M | 654K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 45.12M | 49.16M | 53.13M | 74.09M | 63.8M |
| Selling, General & Admin | 7.17M | 12M | 15.38M | 31.68M | 45.46M |
| Operating Expenses | 52.29M | 61.16M | 68.51M | 105.77M | 109.26M |
| Depreciation & Amortization | 13K | 1.15M | 1.84M | 2M | 2.08M |
| EBITDA | (50.61M) | (58.04M) | (64.35M) | (96.19M) | (97.68M) |
| EBITDA Margin | -3054.3% | -8874.8% | — | — | — |
| Operating Income | (50.64M) | (60.51M) | (68.51M) | (105.77M) | (109.26M) |
| Operating Margin | -3055.9% | -9252.1% | — | — | — |
| Interest Income | 15K | 1.33M | 2.87M | 7.56M | 6.13M |
| Interest Expense | 0 | 91K | 205K | 114K | 206K |
| Other Income / Expenses | 15K | 1.23M | 2.12M | 7.43M | 9.3M |
| Income Before Tax | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Pre-Tax Margin | -3055.0% | -9063.8% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Net Margin | -3055.0% | -9063.8% | — | — | — |
| EPS (Basic) | (2.01) | (2.36) | (2.49) | (3.09) | (1.86) |
| EPS (Diluted) | (2.01) | (2.40) | (2.49) | (3.09) | (1.86) |
| Weighted Avg Shares | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
| Weighted Avg Shares (Diluted) | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.